CD34+CD19-CD22+ B-cell progenitors might underlie phenotypic escape in patients treated with CD19-directed therapies
CD19-directed immunotherapies have revolutionized the treatment of advanced B-ALL. Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. B-ALL patients successfully treated with CD19-directed T-cells eventually relapse, which coupled with the early onset of CD...
প্রধান লেখক: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
বিন্যাস: | Journal article |
ভাষা: | English |
প্রকাশিত: |
American Society of Hematology
2022
|